 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Mar 06, 2024 |
| Title |
22Rv1 THZ531 treated replica 2 |
| Sample type |
SRA |
| |
|
| Source name |
22Rv7
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: 22Rv7
cell type: prostate cancer cell line
treatment: THZ531 200 nM
time: 6 hrs
|
| Treatment protocol |
24hrs post-seeding 22Rv1 cells were treated with Indisulam (3.3µM, 12hrs), or Pladienolide B (10nM, 6hrs) or THZ531 (200Nm, 6hrs) or DMSO, as control.
|
| Growth protocol |
22Rv1 cells were grown in RPMI medium (Euroclone), supplemented with 10% fetal bovine serum, Sodium Pyruvate, HEPES, penicillin and streptomycin (GIBCO, Life Technologies) and glucose (Thermo Fisher)
|
| Extracted molecule |
total RNA |
| Extraction protocol |
total RNA was extracted and DNAse treated using the RNEasy mini kit (Qiagen) according to manufacturer’s instruction
Universal Plus mRNA-Seq kit (Tecan Genomics, Redwood City, CA) has been used for library preparation following the manufacturer’s instructions (library type: fr-secondstrand).
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina NovaSeq 6000 |
| |
|
| Data processing |
Sequencing, data quality, reads repartition (e.g., for potential ribosomal contamination), and insert size estimation were performed using FastQC, Picard-Tools, Samtools and rseqc
Reads were mapped using STAR_2.7.5a
Assembly: hg19
Supplementary files format and content: Gene expression values normalized by DESeq2 unsing FAST DB v2018_1 annotations
|
| |
|
| Submission date |
Jun 12, 2023 |
| Last update date |
Mar 06, 2024 |
| Contact name |
Pierre de la Grange |
| E-mail(s) |
pierre.delagrange@genosplice.com
|
| Organization name |
GenoSplice technology
|
| Department |
Paris Biotech Santé
|
| Street address |
29, rue du Faubourg Saint-Jacques
|
| City |
Paris |
| ZIP/Postal code |
75014 |
| Country |
France |
| |
|
| Platform ID |
GPL24676 |
| Series (1) |
| GSE234734 |
Splicing targeting approaches highlight actionable vulnerabilities in advanced prostate cancer [22Rv1] |
|
| Relations |
| BioSample |
SAMN35716439 |
| SRA |
SRX20662163 |
| Supplementary data files not provided |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
